ReviewFuture oncology (London, England)2025
Cemiplimab in the treatment of metastatic basal cell carcinoma.
Review in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Optimized Whole-Mount X-gal Staining to Detect Hedgehog Signaling Activity in Basal Cell Carcinoma: A Platform for Spatial Integration with Immune Analysis.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Immunopathogenesis and Therapeutic Implications in Basal Cell Carcinoma: Current Concepts and Future Directions.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic basal cell carcinoma (mBCC) is a rare but aggressive form of skin cancer that poses significant therapeutic challenges. Historically, systemic treatment options were limited, with hedgehog pathway inhibitors (HHIs) providing modest efficacy, but poor tolerability long term. This review explores cemiplimab, an immune checkpoint inhibitor targeting PD-1, as a novel therapeutic agent for mBCC. We examine its pharmacologic profile, clinical efficacy in clinical trials, safety and tolerability, and real-world performance. A comprehensive literature review was conducted using PubMed and clinical trial registries to assess cemiplimab's role in mBCC treatment, including its comparison to HHIs and potential in combination or neoadjuvant strategies. Cemiplimab has emerged as a transformative therapy for patients with mBCC who are intolerant to or have progressed on HHIs. Despite lower response rates compared to cutaneous squamous cell carcinoma, cemiplimab offers meaningful and durable disease control with a favorable safety profile and preservation of quality of life. Ongoing research into predictive biomarkers, neoadjuvant use, and combination regimens may further enhance its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.